Atrial fibrillation Circulatory System Atrial fibrillation
Conditions
Interventions
This study is a pilot and feasibility study where participants will be randomly allocated to one of two groups, the intervention or control group. Randomisation will be carried out via secure web-base
Sponsors
Edinburgh Napier University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients: 1. Adults diagnosed with atrial fibrillation 2. Prescribed oral anticoagulant therapy 3. Able to provide written informed consent in English 4. Participants must have access to a personal device (e.g. mobile or tablet) Health care professionals: 1. Healthcare professionals working at study recruitment sites who have had involvement in recruitment of study participants 2. Healthcare professionals working at study recruitment sites who have had involvement in taking blood samples for study participants
Exclusion criteria
Exclusion criteria: Patients: 1. Patients with unstable atrial fibrillation or newly initiated on warfarin 2. Patients with atrial fibrillation who are not prescribed oral anticoagulant therapy 3. Patients who are unable to provide written informed consent in English 4. Patients who do not have access to a personal device (e.g. mobile or tablet) Health care professionals: 1. Healthcare professionals working at study recruitment sites who have not had involvement in recruitment of study participants or taken blood samples for study participants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at week 1, 12 and 24: 1. Medication adherence measured using blood assay measures (Anti-Xa or International Normalised Ratio) 2. Medication adherence measured using the Medication Adherence Rating Scale 3. Beliefs about Medications Questionnaire scores | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quality of life assessed via (SF-12 questionnaire) at baseline, 12 weeks and 24 weeks 2. AF morbidity (e.g. AF related hospitalization) assessed via a self-reported healthcare questionnaire at 12 weeks and 24 weeks 3. Patient barriers and facilitators to using a mobile health app to manage their AF assessed via semi-structured interviews after 12 weeks 4. Healthcare professional experiences of implementing a mobile health app to increase medication adherence between 12 and 24 weeks | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactAlice;Coral Pearson;Hanson
;
Outcome results
None listed